KR101747478B1 - Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트 - Google Patents

Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트 Download PDF

Info

Publication number
KR101747478B1
KR101747478B1 KR1020127030506A KR20127030506A KR101747478B1 KR 101747478 B1 KR101747478 B1 KR 101747478B1 KR 1020127030506 A KR1020127030506 A KR 1020127030506A KR 20127030506 A KR20127030506 A KR 20127030506A KR 101747478 B1 KR101747478 B1 KR 101747478B1
Authority
KR
South Korea
Prior art keywords
formula
moiety
another embodiment
compound
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020127030506A
Other languages
English (en)
Korean (ko)
Other versions
KR20130066622A (ko
Inventor
파트릭 헨리 베우스커
루디 게라르두스 엘리자베쓰 코우만스
로날드 크리스티아안 엘게르스마
위로 미카엘 페트루스 베르나르두스 멘게
요하네스 알베르투스 프레데리쿠스 주스텐
헨리 요하네스 스피즈케르
그루트 프랑시스쿠스 마리누스 헨드리쿠스 데
Original Assignee
신타가 비.브이.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 신타가 비.브이. filed Critical 신타가 비.브이.
Publication of KR20130066622A publication Critical patent/KR20130066622A/ko
Application granted granted Critical
Publication of KR101747478B1 publication Critical patent/KR101747478B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A61K38/385—Serum albumin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A61K47/546—Porphyrines; Porphyrine with an expanded ring system, e.g. texaphyrine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020127030506A 2010-04-21 2011-04-21 Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트 Active KR101747478B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US32643710P 2010-04-21 2010-04-21
US61/326,437 2010-04-21
US42182410P 2010-12-10 2010-12-10
US61/421,824 2010-12-10
PCT/NL2011/050278 WO2011133039A2 (en) 2010-04-21 2011-04-21 Novel conjugates of cc-1065 analogs and bifunctional linkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020177005864A Division KR20170027880A (ko) 2010-04-21 2011-04-21 Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트

Publications (2)

Publication Number Publication Date
KR20130066622A KR20130066622A (ko) 2013-06-20
KR101747478B1 true KR101747478B1 (ko) 2017-06-14

Family

ID=44343209

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020127030506A Active KR101747478B1 (ko) 2010-04-21 2011-04-21 Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트
KR1020177005864A Ceased KR20170027880A (ko) 2010-04-21 2011-04-21 Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트
KR1020187006266A Active KR101901555B1 (ko) 2010-04-21 2011-04-21 Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020177005864A Ceased KR20170027880A (ko) 2010-04-21 2011-04-21 Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트
KR1020187006266A Active KR101901555B1 (ko) 2010-04-21 2011-04-21 Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트

Country Status (23)

Country Link
US (3) US9629924B2 (enExample)
EP (3) EP3056203B1 (enExample)
JP (2) JP6009434B2 (enExample)
KR (3) KR101747478B1 (enExample)
CN (1) CN106749665B (enExample)
AU (2) AU2011243294C1 (enExample)
BR (1) BR112012026953A8 (enExample)
CA (2) CA2796712C (enExample)
CY (3) CY1118072T1 (enExample)
DK (3) DK3108886T3 (enExample)
ES (3) ES2594952T3 (enExample)
HR (3) HRP20161339T1 (enExample)
HU (3) HUE030846T2 (enExample)
LT (3) LT3108886T (enExample)
MX (2) MX374267B (enExample)
NO (1) NO3056203T3 (enExample)
PL (3) PL3108886T3 (enExample)
PT (3) PT3056203T (enExample)
RU (2) RU2730502C2 (enExample)
TR (1) TR201802539T4 (enExample)
UA (1) UA112291C2 (enExample)
WO (1) WO2011133039A2 (enExample)
ZA (1) ZA201208282B (enExample)

Families Citing this family (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8044178B2 (en) 2006-03-10 2011-10-25 Wyeth Llc Anti-5T4 antibodies and uses thereof
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
NO2344478T3 (enExample) 2008-11-03 2018-02-24
MX374267B (es) 2010-04-21 2025-03-06 Syntarga Bv Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales.
AU2013328580B2 (en) 2012-10-12 2016-01-21 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
AU2013364065B2 (en) 2012-12-21 2018-10-04 Altrubio Inc. Hydrophilic self-immolative linkers and conjugates thereof
TWI680766B (zh) * 2013-03-13 2020-01-01 英商梅迪繆思有限公司 吡咯并苯并二氮呯及其共軛物
US9649390B2 (en) 2013-03-13 2017-05-16 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
EP3033111B1 (en) 2013-08-12 2019-03-13 Genentech, Inc. 1-(chloromethyl)-2,3-dihydro-1h-benzo[e]indole dimer antibody-drug conjugate compounds, and methods of use and treatment
BR112016013258A2 (pt) 2013-12-16 2018-01-16 Genentech Inc composto conjugado anticorpo-droga, composição farmacêutica, método para tratar câncer e kit
MX373458B (es) * 2014-01-10 2020-05-11 Byondis Bv Metodo para purificar conjugados de anticuerpo-farmaco enlazados a cisteina.
SG10201911860VA (en) * 2014-01-10 2020-02-27 Synthon Biopharmaceuticals Bv Duocarmycin adcs showing improved in vivo antitumor activity
KR20160099725A (ko) 2014-01-10 2016-08-22 신톤 바이오파머슈티칼즈 비.브이. 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
DK3151865T3 (da) * 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
HRP20191378T1 (hr) 2014-06-05 2019-11-15 Synthon Biopharmaceuticals Bv Poboljšani postupak dobivanja duokarmicinskih predlijekova
SG10201811124YA (en) * 2014-06-20 2019-01-30 Abgenomics Int Inc Her2 antibody-drug conjugates
CA2952876A1 (en) 2014-06-20 2015-12-23 Bioalliance C.V. Anti-folate receptor alpha (fra) antibody-drug conjugates and methods of using thereof
AU2015282627B2 (en) 2014-06-30 2020-04-02 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
GB201416112D0 (en) 2014-09-12 2014-10-29 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
PL3319597T3 (pl) 2015-07-10 2021-10-11 Byondis B.V. Kompozycje zawierające koniugaty przeciwciało-duokarmycyna
EP3352857B1 (en) * 2015-09-22 2021-01-13 Byondis B.V. Syd985 treatment of t-dm1 refractory cancer patients
EP3165237B1 (en) 2015-11-03 2018-12-19 Industrial Technology Research Institute Antibody-drug conjugate (adc) and method for forming the same
AU2016358854B2 (en) * 2015-11-24 2023-02-02 Byondis B.V. Anti-5T4 antibodies and antibody-drug conjugates
TWI753875B (zh) 2016-01-08 2022-02-01 美商美國全心醫藥生技股份有限公司 四價抗psgl-1抗體及其用途
GB201601431D0 (en) 2016-01-26 2016-03-09 Medimmune Ltd Pyrrolobenzodiazepines
GB201602356D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
GB201602359D0 (en) 2016-02-10 2016-03-23 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
PT3458100T (pt) 2016-02-12 2020-08-05 Byondis Bv Redução seletiva de anticorpos modificados por cisteína
EP3442574A4 (en) 2016-04-15 2019-12-11 MacroGenics, Inc. Novel B7-H3 binding MOLECULES, ANTIBODY-ACTIVE CONJUGATES AND METHOD OF USE THEREOF
GB201607478D0 (en) 2016-04-29 2016-06-15 Medimmune Ltd Pyrrolobenzodiazepine Conjugates
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
WO2018035391A1 (en) * 2016-08-19 2018-02-22 Bristol-Myers Squibb Company Seco-cyclopropapyrroloindole compounds, antibody-drug conjugates thereof, and methods of making and use
DK3525826T3 (da) 2016-10-11 2020-08-24 Byondis Bv Ikke-lineære selvofrende linkere og konjugater deraf
GB201617466D0 (en) 2016-10-14 2016-11-30 Medimmune Ltd Pyrrolobenzodiazepine conjugates
WO2018086993A1 (en) 2016-11-14 2018-05-17 Synthon Biopharmaceuticals B.V. PROCESS FOR THE PREPARATION OF MONO-PROTECTED alpha,omega-DIAMINO ALKANES
GB201702031D0 (en) 2017-02-08 2017-03-22 Medlmmune Ltd Pyrrolobenzodiazepine-antibody conjugates
BR112019016373B1 (pt) 2017-02-08 2022-01-25 Medimmune Limited Conjugado anticorpo-fármaco que se liga ao axl, composição e composição farmacêutica que compreende o mesmo e uso terapêutico do dito conjugado
US11370801B2 (en) 2017-04-18 2022-06-28 Medimmune Limited Pyrrolobenzodiazepine conjugates
WO2018209239A1 (en) 2017-05-11 2018-11-15 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN110831976A (zh) 2017-05-23 2020-02-21 斯索恩生物制药有限公司 用于制备抗体-药物缀合物的双重缀合方法
PT3668874T (pt) 2017-08-18 2022-02-24 Medimmune Ltd Conjugados de pirrolobenzodiazepina
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
CN120789287A (zh) 2017-10-23 2025-10-17 马布林克生物科学公司 包含单分子量聚肌氨酸的配体-药物-缀合物
PT3713939T (pt) 2017-11-24 2021-09-16 Byondis Bv Processo melhorado para a síntese de fármaco ligante vcseco- duba
JP7165193B2 (ja) 2017-11-27 2022-11-02 パーデュー、ファーマ、リミテッド、パートナーシップ ヒト組織因子を標的とするヒト化抗体
GB201803342D0 (en) 2018-03-01 2018-04-18 Medimmune Ltd Methods
GB201806022D0 (en) 2018-04-12 2018-05-30 Medimmune Ltd Pyrrolobenzodiazepines and conjugates thereof
CA3116234A1 (en) 2018-10-15 2020-04-23 Merck Patent Gmbh Combination therapy utilizing dna alkylating agents and atr inhibitors
HUE059919T2 (hu) 2018-11-09 2023-01-28 Byondis Bv Duokarmicintartalmú antitest-hatóanyag konjugátum szûrhetõ készítményei és ezekkel kapcsolatos eljárások
MX2021010477A (es) 2019-03-15 2021-10-01 Medimmune Ltd Dimeros de azetidobenzodiazepina y conjugados que los comprenden para uso en el tratamiento de cancer.
US11535634B2 (en) 2019-06-05 2022-12-27 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
BR112022015062A2 (pt) 2020-02-06 2022-09-20 Byondis Bv Conjugado anticorpo-fármaco para uso no tratamento de um tumor, composição, uso de um conjugado anticorpo-fármaco, produto compreendendo um conjugado anticorpo-fármaco, e, método para prevenção ou redução da toxicidade associada à administração de um conjugado anticorpo-fármaco
AU2021306557A1 (en) 2020-07-06 2023-02-02 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
US20220008511A1 (en) * 2020-07-12 2022-01-13 Henry J. Smith Tumor treatment using cytokines and cancer drugs
CN114867481A (zh) * 2020-07-27 2022-08-05 艾斯法姆生物技术股份有限公司 与cd151相关的兽医学疾患的治疗
US12030888B2 (en) 2021-02-24 2024-07-09 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
MX2023011929A (es) 2021-04-08 2023-10-23 Byondis Bv Anticuerpos anti-c-met y conjugados de anticuerpo-farmaco.
IL309249A (en) 2021-06-28 2024-02-01 Byondis Bv Conjugates including phosphoantigens and their use in therapy
JP7753523B2 (ja) * 2021-11-02 2025-10-14 煙台邁百瑞国際生物医薬股▲ふん▼有限公司 Ｓｎ３８を含む抗体－薬物コンジュゲートの中間体及びその調製方法
CA3242777A1 (en) 2021-12-30 2023-07-06 Byondis B.V. Antifolate linker-drugs and antibody-drug conjugates
KR20250011922A (ko) 2022-05-16 2025-01-22 비온디스 비.브이. 신규한 차폐된 항체
WO2024133374A1 (en) 2022-12-22 2024-06-27 Byondis B.V. Novel linker drugs comprising phosphoantigens, novel conjugates and their use in therapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097635A1 (en) 2002-05-17 2003-11-27 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl(amine-derived)] compounds and analogues thereof, and to products obtained therefrom
WO2004101767A2 (en) 2003-05-13 2004-11-25 The Scripps Research Institute Cbi analogues of the duocarmycins and cc-1065

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2098331A (en) 1981-05-12 1982-11-17 Sangamo Weston Controls Parallel motion displacement transducers
CA1238907A (en) 1984-02-21 1988-07-05 Robert C. Kelly 1,2,8,8a-tetrahydrocyclopropa¬c|pyrrolo(3,2-e)- indol-4(5h)-ones and related compounds
US4771128A (en) 1986-10-10 1988-09-13 Cetus Corporation Method of purifying toxin conjugates using hydrophobic interaction chromatography
WO1988004659A2 (en) 1986-12-19 1988-06-30 The Upjohn Company Novel cc-1065 analogs
AU632288B2 (en) 1988-09-12 1992-12-24 Pharmacia & Upjohn Company Novel cc-1065 analogs having two cpi subunits
AU648313B2 (en) * 1990-04-25 1994-04-21 Pharmacia & Upjohn Company Novel CC-1065 analogs
DE69231123T2 (de) 1992-03-25 2001-02-15 Immunogen Inc Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
JP3514490B2 (ja) * 1992-08-21 2004-03-31 杏林製薬株式会社 トリフルオロメチルピロロインドールカルボン酸エステル誘導体及びその製造方法
GB9307491D0 (en) 1993-04-08 1993-06-02 Sandoz Ltd Organic compounds
AU689566B2 (en) 1994-04-01 1998-04-02 Kyowa Hakko Kogyo Co. Ltd. DC-89 derivatives
JPH07309761A (ja) 1994-05-20 1995-11-28 Kyowa Hakko Kogyo Co Ltd デュオカルマイシン誘導体の安定化法
US5502068A (en) * 1995-01-31 1996-03-26 Synphar Laboratories, Inc. Cyclopropylpyrroloindole-oligopeptide anticancer agents
DE19503320A1 (de) 1995-02-02 1996-08-08 Boehringer Mannheim Gmbh Neue Benzodiazepinkonjugate
US5646298A (en) 1995-06-07 1997-07-08 Procoron, Inc. Cyclopropylindole prodrugs
GB9516943D0 (en) 1995-08-18 1995-10-18 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their secoprecursors,and their use as prodrugs
US6548530B1 (en) 1995-10-03 2003-04-15 The Scripps Research Institute CBI analogs of CC-1065 and the duocarmycins
ATE301639T1 (de) 1996-03-08 2005-08-15 Scripps Research Inst Mcbi analoge von cc-1065 und die duocarmycine
US5843937A (en) * 1996-05-23 1998-12-01 Panorama Research, Inc. DNA-binding indole derivatives, their prodrugs and immunoconjugates as anticancer agents
CA2255703A1 (en) 1996-05-31 1997-12-04 Dale L. Boger Analogs of cc-1065 and the duocarmycins
ATE310725T1 (de) * 1996-09-12 2005-12-15 Auckland Uniservices Ltd Kondensierte n-acylindole als antitumormittel
WO1998025900A1 (en) 1996-12-13 1998-06-18 Shionogi & Co., Ltd. Compounds having antitumor activity
GB9625913D0 (en) 1996-12-13 1997-01-29 Cancer Soc Auckland Div Nz Inc Novel cyclopropylindoles and their seco precursors,and their use as prodrugs
ATE271041T1 (de) 1997-05-22 2004-07-15 Scripps Research Inst Analoga von duocarmycin and cc-1065
US6262271B1 (en) 1997-10-14 2001-07-17 The Scripps Research Institute ISO-CBI and ISO-CI analogs of CC-1065 and the duocarmycins
US20030036629A1 (en) 1997-12-12 2003-02-20 Barry Foster Novel tgf-beta protein purification methods
WO2001083448A2 (de) 2000-05-02 2001-11-08 Tietze Lutz F Neue prodrugs von 6-hydroxy-2,3-dihydro-1h-indolen, 5-hydroxy-1,2-dihydro-3h-pyrrolo[3,2-e]indolen und 5-hydroxy-1,2-dihydro-3h-benzo[e]indolen sowie von 6-hydroxy-1,2,3,4-tetrahydro-benzo[f]chinolin-derivaten für eine selektive krebstherapie
AU2001262974A1 (en) 2000-05-03 2001-11-12 The Scripps Research Institute Dna alkylating agent and activation thereof
DE60115265T2 (de) * 2000-09-19 2006-08-10 Lee, Moses, Holland Zusammensetzungen und verfahren zur verwendung achiraler analoge von cc-1065 und den duocarmycinen
EP1363908A4 (en) * 2001-01-24 2004-05-06 Auckland Uniservices Ltd ANTI-CANCER COMPLEXES 2,3-DIHYDRO-1H-PYRROLO 3,2-F] COBALT AND CHROME QUINOLINE
EP1408970B1 (en) 2001-02-22 2007-05-09 School Of Pharmacy, University Of London Indolines and tetrahydro-quinolines as prodrugs for tumour treatment
US7192977B2 (en) 2001-02-22 2007-03-20 School Of Pharmacy Benz-indole and benzo-quinoline derivatives as prodrugs for tumor treatment
ES2299560T3 (es) 2001-02-22 2008-06-01 University Of Bradford Derivados de pirrolindol y de pirroloquinolina como profarmacos para el tratamiento de tumores.
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
WO2002096910A1 (en) * 2001-05-31 2002-12-05 Medarex, Inc. Cytotoxins, prodrugs, linkers and stabilizers useful therefor
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP2005502703A (ja) * 2001-09-07 2005-01-27 ザ スクリプス リサーチ インスティテュート Ｃｃ−１０６５およびデュオカルマイシンのｃｂｉ類似体
US6756397B2 (en) 2002-04-05 2004-06-29 Immunogen, Inc. Prodrugs of CC-1065 analogs
WO2004043493A1 (en) 2002-11-14 2004-05-27 Syntarga B.V. Prodrugs built as multiple self-elimination-release spacers
AR042942A1 (es) 2003-01-27 2005-07-06 Endocyte Inc Conjugados de administracion de drogas de union de receptores de vitaminas
US20070037739A1 (en) 2003-02-03 2007-02-15 Medlogics Device Corporation Compounds useful in coating stents to prevent and treat stenosis and restenosis
ATE472338T1 (de) 2003-02-20 2010-07-15 Seattle Genetics Inc Anti-cd70 antikörper-arzneimittelkonjugate und ihre verwendung zur behandlung von krebs
WO2005032594A2 (en) * 2003-10-03 2005-04-14 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Alkylators linked to polyamides as dna binding agents
US7282590B2 (en) 2004-02-12 2007-10-16 The Research Foundation Of State University Of New York Drug conjugates
WO2005084390A2 (en) 2004-03-02 2005-09-15 Seattle Genetics, Inc. Partially loaded antibodies and methods of their conjugation
CN1997399A (zh) 2004-04-21 2007-07-11 阿尔扎公司 可在温和硫解条件下释放的聚合物共轭物
US20050239864A1 (en) 2004-04-23 2005-10-27 Yuqiang Wang Novel tumor-selective chemotherapeutic agents
WO2005112919A2 (en) 2004-05-19 2005-12-01 Medarex, Inc. Self-immolative linkers and drug conjugates
KR20070037719A (ko) 2004-06-30 2007-04-06 노파르티스 아게 항종양제로서의 항체와 듀오카르마이신 유도체의컨쥬게이트
EP1789391B1 (en) 2004-07-23 2017-06-28 Endocyte, Inc. Bivalent linkers and conjugates thereof
TR201808537T4 (tr) 2004-09-23 2018-07-23 Genentech Inc Sistein değiştirilmiş antikorlar ve konjugatlar.
AU2005289453A1 (en) 2004-09-27 2006-04-06 Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services, National Institutes of Health Modulating MxA expression
NZ536107A (en) 2004-10-22 2007-06-29 Auckland Uniservices Ltd Nitrobenzindoles and their use in cancer therapy
EP1858902A1 (en) 2005-02-24 2007-11-28 Pfizer Products Incorporated Bicyclic heteroaromatic derivatives useful as anticancer agents
US7714016B2 (en) 2005-04-08 2010-05-11 Medarex, Inc. Cytotoxic compounds and conjugates with cleavable substrates
FR2884252B1 (fr) * 2005-04-08 2007-05-18 Aventis Pharma Sa Nouveaux derives d'isoindoles, compositions les contenant, leur preparation et leurs utilisations pharmaceutiques notamment en tant qu'inhibiteurs d'activites de la proteine chaperone hsp90
AU2006277117B2 (en) 2005-08-05 2013-01-10 Syntarga B.V. Triazole-containing releasable linkers and conjugates comprising the same
NZ566982A (en) * 2005-09-26 2011-06-30 Medarex Inc Duocarmycin drug conjugates
ATE534629T1 (de) * 2005-10-26 2011-12-15 Medarex Inc Verfahren und verbindungen zur herstellung von cc-1065-analoga
CA2627190A1 (en) 2005-11-10 2007-05-24 Medarex, Inc. Duocarmycin derivatives as novel cytotoxic compounds and conjugates
MX2008009956A (es) 2006-02-02 2008-12-12 Syntarga Bv Analogos de cc-1065 solubles en agua y sus conjugados.
EP1832577A1 (en) 2006-03-07 2007-09-12 Sanofi-Aventis Improved prodrugs of CC-1065 analogs
CA3125026C (en) 2006-11-01 2023-04-04 Ventana Medical Systems, Inc. Haptens, hapten conjugates, compositions thereof and method for their preparation and use
EP2097534A4 (en) 2006-12-14 2010-05-12 Medarex Inc HUMAN ANTIBODIES BINDING TO CD70 AND USES THEREOF
TWI412367B (zh) 2006-12-28 2013-10-21 Medarex Llc 化學鏈接劑與可裂解基質以及其之綴合物
AR065404A1 (es) 2007-02-21 2009-06-03 Medarex Inc Conjugados farmaco-ligando, los que se unen a citotoxinas potentes, composicion farmaceutica que los contienen y su uso para retardar o detener el crecimiento de un tumor en un mamifero
US9901567B2 (en) 2007-08-01 2018-02-27 Syntarga B.V. Substituted CC-1065 analogs and their conjugates
WO2009017394A1 (en) 2007-08-01 2009-02-05 Syntarga B.V. Substituted cc-1065 analogs and their conjugates
WO2009026274A1 (en) 2007-08-22 2009-02-26 Medarex, Inc. Site-specific attachment of drugs or other agents to engineered antibodies with c-terminal extensions
EP2227087B1 (en) * 2007-11-13 2013-10-09 The Scripps Research Institute Cbi derivatives subject to reductive activation
TW200938224A (en) 2007-11-30 2009-09-16 Medarex Inc Anti-B7H4 monoclonal antibody-drug conjugate and methods of use
US20090162372A1 (en) 2007-11-30 2009-06-25 Medarex, Inc. Fibronectin ed-b antibodies, conjugates thereof, and methods of use
EP2211908A2 (en) 2007-11-30 2010-08-04 Bristol-Myers Squibb Company Conjugates of anti-rg-1 antibodies
EP2229187A2 (en) 2007-11-30 2010-09-22 Bristol-Myers Squibb Company Monoclonal antibody partner molecule conjugates directed to protein tyrosine kinase 7 (ptk7)
KR101764927B1 (ko) 2008-04-30 2017-08-03 이뮤노젠 아이엔씨 가교제 및 그 용도
NZ571028A (en) 2008-09-03 2011-01-28 Auckland Uniservices Ltd Nitrobenzindole compounds and their use in cancer treatment
JP5675619B2 (ja) * 2008-09-17 2015-02-25 エンドサイト, インク.Endocyte, Inc. 葉酸拮抗薬の葉酸受容体結合性コンジュゲート
NO2344478T3 (enExample) 2008-11-03 2018-02-24
WO2011022316A1 (en) 2009-08-20 2011-02-24 The Regents Of The University Of Colorado, A Body Corporate Mirnas dysregulated in triple-negative breast cancer
MX374267B (es) 2010-04-21 2025-03-06 Syntarga Bv Conjugados novedosos de analogos cc-1065 y ligaduras bifuncionales.
US9958455B2 (en) 2011-09-29 2018-05-01 Seattle Genetics, Inc. Intact mass determination of protein conjugated agent compounds
BR112014007521A8 (pt) 2011-10-14 2018-04-10 Genentech Inc método para estender a sobrevida livre de progressão em uma população com câncer de mama, artigo de fabricação, método para produção de um artigo de fabricação, para garantir o uso seguro e efetivo de pertuzumabe, de tratar câncer de mama, bolsa intravenosa, método de tratar câncer gástrico, de tratar adenocarcinoma do estômago e de melhora de sobrevida
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
SG10201911860VA (en) 2014-01-10 2020-02-27 Synthon Biopharmaceuticals Bv Duocarmycin adcs showing improved in vivo antitumor activity
MX373458B (es) 2014-01-10 2020-05-11 Byondis Bv Metodo para purificar conjugados de anticuerpo-farmaco enlazados a cisteina.
KR20160099725A (ko) 2014-01-10 2016-08-22 신톤 바이오파머슈티칼즈 비.브이. 자궁내막암의 치료에서 사용하기 위한 듀오카르마이신 adc
DK3151865T3 (da) 2014-05-22 2021-10-25 Byondis Bv Stedsspecifik konjugation af linker medicin til antistof og resulterende adcs
HRP20191378T1 (hr) 2014-06-05 2019-11-15 Synthon Biopharmaceuticals Bv Poboljšani postupak dobivanja duokarmicinskih predlijekova
US20170320965A1 (en) 2014-09-22 2017-11-09 Synthon Biopharmaceuticals B.V. Pan-reactive antibodies to duocarmycins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003097635A1 (en) 2002-05-17 2003-11-27 Auckland Uniservices Limited Processes for preparing 3-substituted 1-(chloromethyl)-1,2-dihydro-3h-[ring fused indol-5-yl(amine-derived)] compounds and analogues thereof, and to products obtained therefrom
WO2004101767A2 (en) 2003-05-13 2004-11-25 The Scripps Research Institute Cbi analogues of the duocarmycins and cc-1065

Also Published As

Publication number Publication date
RU2016101244A (ru) 2017-07-21
US20170333567A1 (en) 2017-11-23
AU2011243294A1 (en) 2012-11-15
NO3056203T3 (enExample) 2018-05-12
AU2015213336B2 (en) 2016-07-21
US20180147289A9 (en) 2018-05-31
HUE036912T2 (hu) 2018-08-28
WO2011133039A3 (en) 2012-04-12
ES2594952T3 (es) 2016-12-27
EP3108886A3 (en) 2017-03-22
ES2815678T3 (es) 2021-03-30
JP6009434B2 (ja) 2016-10-19
RU2016101244A3 (enExample) 2019-07-24
UA112291C2 (uk) 2016-08-25
MX336853B (es) 2016-01-19
BR112012026953A8 (pt) 2022-11-22
DK2560645T3 (en) 2016-10-10
PT3108886T (pt) 2020-08-27
EP3056203A1 (en) 2016-08-17
MX374267B (es) 2025-03-06
AU2011243294C1 (en) 2015-12-03
JP2016183156A (ja) 2016-10-20
AU2015213336A1 (en) 2015-09-03
KR20170027880A (ko) 2017-03-10
DK3108886T3 (da) 2020-08-10
HUE050508T2 (hu) 2020-12-28
MX2012012176A (es) 2012-12-17
EP2560645B1 (en) 2016-07-13
KR20130066622A (ko) 2013-06-20
US20170274090A1 (en) 2017-09-28
PL2560645T3 (pl) 2017-01-31
HRP20161339T1 (hr) 2016-11-18
CA2796712A1 (en) 2011-10-27
CY1118072T1 (el) 2017-06-28
CY1124632T1 (el) 2022-03-24
JP2013525347A (ja) 2013-06-20
JP6193433B2 (ja) 2017-09-06
EP3108886B1 (en) 2020-06-17
CN106749665B (zh) 2021-03-26
ZA201208282B (en) 2014-01-29
KR20180029083A (ko) 2018-03-19
CA2956934A1 (en) 2011-10-27
PL3056203T3 (pl) 2018-06-29
LT2560645T (lt) 2016-10-10
DK3056203T3 (da) 2018-01-29
WO2011133039A2 (en) 2011-10-27
LT3108886T (lt) 2020-08-25
HUE030846T2 (en) 2017-06-28
BR112012026953A2 (pt) 2018-07-10
CA2796712C (en) 2017-02-28
EP3108886A2 (en) 2016-12-28
LT3056203T (lt) 2018-03-26
RU2012149448A (ru) 2014-05-27
US20180133316A9 (en) 2018-05-17
RU2578719C2 (ru) 2016-03-27
PT2560645T (pt) 2016-10-24
EP3056203B1 (en) 2017-12-13
CA2956934C (en) 2019-07-09
HRP20201446T1 (hr) 2021-03-05
CY1119893T1 (el) 2018-06-27
RU2730502C2 (ru) 2020-08-24
PT3056203T (pt) 2018-02-15
ES2660428T3 (es) 2018-03-22
HRP20180209T1 (hr) 2018-03-09
RU2578719C9 (ru) 2016-10-10
AU2011243294B2 (en) 2015-06-04
EP2560645A2 (en) 2013-02-27
HRP20201446T8 (hr) 2021-08-20
US9629924B2 (en) 2017-04-25
TR201802539T4 (tr) 2018-03-21
US20130224227A1 (en) 2013-08-29
PL3108886T3 (pl) 2021-01-11
US11052155B2 (en) 2021-07-06
KR101901555B1 (ko) 2018-09-21
CN106749665A (zh) 2017-05-31
CN103118679A (zh) 2013-05-22

Similar Documents

Publication Publication Date Title
KR101747478B1 (ko) Ｃｃ―１０６５ 유사체와 2작용성 링커의 신규한 콘쥬게이트
JP5905559B2 (ja) 新規ｃｃ−１０６５類似体およびその複合体
CN103118679B (zh) Cc‑1065类似物和双功能接头的缀合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20121121

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20150827

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160708

Patent event code: PE09021S01D

PE0601 Decision on rejection of patent

Patent event date: 20170131

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20160708

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20170302

PX0901 Re-examination

Patent event code: PX09011S01I

Patent event date: 20170131

Comment text: Decision to Refuse Application

Patent event code: PX09012R01I

Patent event date: 20160831

Comment text: Amendment to Specification, etc.

Patent event code: PX09012R01I

Patent event date: 20150827

Comment text: Amendment to Specification, etc.

PX0701 Decision of registration after re-examination

Patent event date: 20170331

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20170302

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20170131

Comment text: Decision to Refuse Application

Patent event code: PX07011S01I

Patent event date: 20160831

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20150827

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20170608

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20170608

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20200529

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20210526

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20220526

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20240530

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20250529

Start annual number: 9

End annual number: 9